Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
decaffeinated green tea extract plus
- Development stage
- Preclinical
- Administration
- Oral
01
Overview
Decaffeinated green tea extract plus (dGTE+) is a dietary supplement combining decaffeinated green tea extract (standardized to 400 mg/d (-)-epigallocatechin-3-gallate or EGCG), quercetin (50 mg/d), and alpha-lipoic acid (150 mg/d). This combination has been investigated for its effects on fat oxidation, body composition, and cardio-metabolic health in overweight individuals engaged in regular exercise. Clinical studies have shown that dGTE+ can improve maximal fat oxidation and substrate utilization during exercise, and also lead to a reduction in LDL-c.
- Other names
- dGTE+
02
Targets
COMT (Catechol-O-methyltransferase)
Beyond the preview
Go deeper on decaffeinated green tea extract plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on decaffeinated green tea extract plus.